Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition-Reference-Cited by-同舟云学术

Mesenchymal stromal cells as treatment or prophylaxis for acute or chronic graft-versus-host disease in haematopoietic stem cell transplant (HSCT) recipients with a haematological condition

Published:2019-01-30 Issue:1 Volume:2019 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

Fisher Sheila A¹,Cutler Antony²,Doree Carolyn¹,Brunskill Susan J¹,Stanworth Simon J³,Navarrete Cristina⁴,Girdlestone John⁴⁵

Affiliation:

1. NHS Blood and Transplant; Systematic Review Initiative; Level 2, John Radcliffe Hospital Headington Oxford Oxon UK OX3 9BQ

2. NHS Blood and Transplant; Histocompatibility & Immunogenetics Research Group; London UK

3. Oxford University Hospitals NHS Foundation Trust and University of Oxford; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre; John Radcliffe Hospital, Headley Way Headington Oxford UK OX3 9BQ

4. University College London; Division of Infection and Immunity; London UK

5. NHS Blood and Transplant; Stem Cells and Immunotherapies; Headley Way Oxford UK OX3 9BQ

Publisher

Wiley

Subject

Pharmacology (medical)

Link

https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009768.pub2/epdf/full

Reference123 articles.

1. ChiCTR-IOR-15006330 Disease after HLA-haploidentical stem cell transplantation - A prospective, randomized, parallel-group study http://www.chictr.org.cn/showproj.aspx?proj=10892

2. Phase II multicenter, randomized, double-blind controlled study of efficacy and safety of umbilical cord-derived mesenchymal stromal cells in the prophylaxis of chronic graft-versus-host disease after HLA-haploidentical stem-cell transplantation;Gao;Journal of Clinical Oncology,2016

3. Co-transplantation of HLA-matched related donors culture-expanded mesenchymal stromal cells and hematopoietic stem cells in thalassemia major patients;Ghavamzadeh;Biology of Blood and Marrow Transplantation,2010

4. Hematopoietic stem cell transplantation for major thalassemia: Nineteen years experience in Iran;Ghavamzadeh;Biology of Blood and Marrow Transplantation,2010

5. EUCTR2008-004014-27-ES Randomized and controlled multicentre phase I/II clinical trial for the safety assessment and feasibility of therapy with two different doses of mesenchymal stem cells from adipose tissue in patients with extensive graft-versus-host disease https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-004014-27

Cited by 72 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mesenchymal stromal cells in the treatment of pediatric hematopoietic cell transplantation-related complications (graft vs. host disease, hemorrhagic cystitis, graft failure and poor graft function): a single center experience;Frontiers in Pediatrics;2024-05-09

2. The Management of Chronic Graft-Versus-Host Disease Skin Ulcers after Hematopoietic Stem Cell Transplantation: A Case Report;Advances in Skin & Wound Care;2024-04

3. Placenta-Derived Decidua Stromal Cells: A New Frontier in the Therapy of Acute Graft-Versus-Host Disease;Stem Cells;2024-01-10

4. Mesenchymal stem cell-derived exosomes for managing graft-versus-host disease: An updated view;Transplant Immunology;2023-12

5. Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease;Journal of Translational Medicine;2023-11-21